Couldn't agree more. The word is already out there about what cellular therapy can do and how it may be a game changer. Other similar companies (i.e. VCEL, APOP, etc) have benefited from the buzz. For Pluristem being so well positioned in this market and not participating is a big disappointment. At this stage management must be playing at least some negative role. I'm still taking a chance on this only for the science but the way this company behaves in the market is very troublesome.
News 
Market Data 
Discover 
